Author Bio A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math. What happened Shares of clinical-stage biopharmaceutical company Rubius Therapeutics (NASDAQ:RUBY) are soaring through the roof on Monday following the company's release of data from an ongoing clinical trial for RTX-240, an experimental cancer treatment. Rubius Therapeutics' stock was up by 71.8% as of 1:08 p.m. EDT after jumping by as much as 135.6% earlier in the day.